Here, we demonstrated that i.t. injection of CV8102 can modulate the tumor microenvironment, increase immune activation, and improve anti-tumor responses; an effect that was enhanced by concomitant systemic anti-PD-1 antibody treatment. This evidence concerns the gene PDCD1 and neoplasm.